Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-210 in Japanese Participants With Bladder Cancer
NCT05567185Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erdafitinib in bladder cancer, sponsored by Janssen Pharmaceutical. Primary endpoint: Dose-limiting Toxicity at 28 days. Started Mar 2023; status: completed.
02
Drugs
erdafitinib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05567185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567185.